This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland

Content Hub

TIDES Insights: Your Year-Round Gateway to Oligonucleotide & Peptide Innovation

Browse key topics and session spotlights from our curated agenda including CMC efficiency, genome editing and the European regulatory landscape for oligonucleotides and peptides.

Key themes for 2025

Elevate your industry knowledge with best practices, innovation and transformative solutions spanning discovery to market, presented by leading experts across multiple disciplines through immersive keynotes, strategic panels and high-value networking experiences.

Here are just a few of the many themes TIDES Europe will cover:

Oligonucleotide Chemistry, Manufacturing & Controls (CMC)
Peptide Process Development and Scale-Up
mRNA Therapeutics Development
Drug Delivery Systems for Oligonucleotides
Analytical Development for TIDES Therapeutics

Accelerating Therapeutics to Market
R&D Expedition Strategies
CMC Efficiency Improvement
Partnering Strategies from Discovery to Market
European Regulatory Landscape for Oligonucleotides and Peptides

Genome Editing Technologies
Sustainability in TIDES Manufacturing
Formulation Science for Stability and Efficacy
Tech Transfer and Scale-Up Challenges
Next-Generation Therapeutic Modalities

Session Spotlights

Explore how AI foundation models are revolutionizing drug discovery by replacing narrow, task-specific approaches with comprehensive systems that benefit from breadth of application and task synergies. This session will demonstrate how these models scale accuracy with increasing data and apply to ASOs, siRNAs, mRNAs, DNA/RNA editing, and target discovery.

How do peptides unlock a new possibility for dissolving neurotoxic protein aggregates, which are a hallmark to various neurodegenerative disorders? This session will focus on the development of PRI-002 from discovery to phase II in Alzheimer’s disease.

Delve into the distinct approaches to process optimization across project phases, with early phase focusing on speed through innovative building blocks and non-standard oligonucleotide synthesis protocols. This session will look at how late phase optimization shifts priority to quality factors, cost reduction, scalability, and efficiency, leveraging accumulated process data and real-world evidence.

Uncover oligonucleotide therapeutics' potential for treating conditions with no current therapies, noting their recent approval surge and unique position between small molecules and biologicals. The presentation will introduce the European Medicines Agency's new draft "Guideline on the Development and Manufacture of Oligonucleotides," addressing the specific quality considerations essential for this innovative therapeutic class.

Key Topics Being Explored at TIDES Europe

expand_less

What analytical methods will be discussed for characterizing oligonucleotide impurities?

The conference will cover advanced analytical techniques including ion-pair reversed-phase liquid chromatography coupled with mass spectrometry (IP-RP LC-MS), high-resolution accurate mass (HRAM) spectrometry, and data-dependent MS2 (ddMS2) methods. Sessions will specifically address how these techniques enable identification and quantification of oligonucleotide impurities and degradation products, even at very low levels.